trending Market Intelligence /marketintelligence/en/news-insights/trending/n-m4mmk5n0chgeuathwlig2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Ono Pharmaceutical secures license for antibody discovery platform

L.K. Bennett: Bankruptcy Case Study

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry


Ono Pharmaceutical secures license for antibody discovery platform

Ono Pharmaceutical Co. Ltd. secured a global license for Ligand Pharmaceuticals' OmniAb platform to discover antibody-based treatments for diseases.

The agreement provides for the OmniRat, OmniMouse and OmniFlic platforms to formulate fully human mono- and bispecific antibodies.

Ligand will receive an undisclosed annual payment for access to the platform as well as milestone-related payments and royalty on sales of products derived from the platform.